The 2022 JADPRO Live conference was held in person from October 20 to 23 in Aurora, Colorado. I was excited to finally see peers I had only met virtually throughout these past 2 years. Numerous advanced practitioner–designed sessions on ...
The lack of diversity in cancer trials is a multifaceted, decades-old problem that has remained persistent despite efforts to increase the number of participants from underrepresented racial and ethnic backgrounds. This lack of meaningfu...
Background: The continued increase in the number of cancer survivors is encouraging and credited to better prevention, screening, and treatment. Cancer care authorities call for survivorship follow-up focusing on surveillance, health beh...
Background and Purpose: Clinical guidelines suggest that prophylactic antiepileptic drugs (AEDs) should be given to newly diagnosed seizure-naive brain tumor patients for up to 1 week after craniotomy. Yet, data suggest that prophylactic...
Lung cancer is the leading cause of cancer-related deaths in the United States. The 5-year survival rates are poor with traditional therapy alone. New scientific advances in technology involving the human genome, including diagnostic too...
Background: Pegfilgrastim is recommended to be administered at least 24 hours following the completion of chemotherapy, yet some clinicians use a same-day administration protocol. In this meta-analysis, we compared the incidence of chemo...
KRAS mutations are the most common alteration in human cancers, accounting for approximately 30% of mutations in multiple cancer types, including colorectal, pancreatic, non–small lung cancer, and ovarian. Of these, the KRAS p.G12C mutat...
With the aging population and increasing number of cancer survivors contributing to a projected provider shortage, one solution is the specialization of nurse practitioners and physician assistants (part of the advanced practice provider...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare cancer with primary sites in the skin and bone marrow and secondary sites in the lymph nodes, spleen, and central nervous system. First described in the 1990s, these cells ex...
